title: Correlation between aqueous flare and chorioretinal neovascularization in age-related macular degeneration following intravitreal bevacizumab injections.
abstract: OBJECTIVE
  Prospective evaluation of aqueous flare following intravitreal bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) injections in eyes with choroidal neovascularization due to age-related macular degeneration.
  
  
  METHODS
  Sixteen eyes of eight patients were recruited. Aqueous humor flare was determined by laser flare meter every month after one intravitreal injection of 1.25mg of bevacizumab at baseline followed by a second injection at month3 (day 100±21days). Four patients received an injection at month6 (±10days), and one patient received an injection at month7.
  
  
  RESULTS
  Two months after the first intravitreal bevacizumab injection, flare values decreased from 10±5.57 (mean±standard deviation) to 5.2±1.69photon count/ms (P=0.0207) and from 8.3±3.59 to 5.4±0photon counts/ms, 2months after the second injection (P=0.02).
  
  
  CONCLUSIONS
  Significantly decreased aqueous humor flare levels were noted after repeated injections of bevacizumab.
authors.affiliation: Department of Ophthalmology IV, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France. Electronic address: marie-helene.errera@orange.fr.
authors.forename: M-H
authors.initials: MH
authors.lastname: Errera
authors.affiliation: Department of Ophthalmology IV, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: J-F
authors.initials: JF
authors.lastname: Girmens
authors.affiliation: Department of Ophthalmology IV, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Ayello-Scheer
authors.affiliation: Department of Pharmacy, université Pierre et Marie Curie-Paris-6, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Nourry
authors.affiliation: Department of Pharmacy, université Pierre et Marie Curie-Paris-6, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Warnet
authors.affiliation: Department of Ophthalmology IV, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: J-A
authors.initials: JA
authors.lastname: Sahel
authors.affiliation: Department of Ophthalmology IV, Centre hospitalier National des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
authors.forename: P-O
authors.initials: PO
authors.lastname: Barale
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000187:drug effects*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D015861:Retinal Neovascularization / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Age macular degeneration; Bevacizumab; Chorioretinal neovascularization; Dégénérescence maculaire liée à l’âge; Flare; Néovascularisation choriorétinienne